Literature DB >> 23674754

Reply to "What types of Candida infections should be included when evaluating breakthrough infections during posaconazole prophylaxis?".

Michael J Dolton, Andrew J McLachlan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23674754      PMCID： PMC3716185          DOI： 10.1128/AAC.00592-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  3 in total

1.  What types of Candida infections should be included when evaluating breakthrough infections during posaconazole prophylaxis?

Authors:  Ola Blennow; Mats Kalin
Journal:  Antimicrob Agents Chemother       Date:  2013-06       Impact factor: 5.191

2.  Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Authors:  Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

3.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.